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INTRODUCTION
Distribution and determinants of heart disease vary greatly 
between high-income countries and sub-Saharan Africa where 
rheumatic heart disease (RHD) is a major public health chal-
lenge.(1) RHD is the predominant cause of valve disease in 
Africa,(2) resulting in Africa having the highest prevalence of 
cardiac disease in children and young adults.(1) Cumulative 
effects of poverty, social instability and lack of infrastructure, 
resources and awareness contribute to the underestimated 
impact of RHD.(1, 2) Studies from Africa confirm that RHD is 
the main cause of cardiac morbidity and mortality from heart 
surgery.(1-3)
Mitral valve disease, in the form of mitral stenosis and mitral 
regurgitation, is the commonest form of valve disease and its 
treatment usually involves surgical repair or replacement. These 
surgical procedures are highly invasive and not without risk of 
complications.(3) In South Africa, data on the management and 
outcomes of mitral valve surgery are limited.(4) Operative mor-
tality in mitral valve replacement surgery is 5% - 6% and 1% - 
2% in mitral valve repair.(5) Complications associated with 
mitral valve surgery are commonly related to cardiopulmonary 
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Background: The distribution and determinants of 
heart disease vary greatly between high-income coun-
tries and sub-Saharan Africa where rheumatic heart 
disease (RHD) is a major public health challenge. Studies 
from Africa report that RHD is the main cause of 
cardiovascular morbidity and mortality in the young. 
Data on mitral valve surgery outcomes in South Africa 
are limited. The aim of this study was to describe the 
peri-operative outcomes of patients that have under-
gone mitral valve surgery at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH).  
Methods: All patients older than 18 years who under-
went mitral valve surgery at CMJAH between 1 January 
2015 and 31 December 2018 were retrospectively 
included. Cardiac intensive care records including 
anaesthesia charts were assessed to describe pre-
operative, intra-operative and post-operative data of 
each patient. Pre-operative data included patient 
demographics and comorbidities. Intra-operative data 
included aortic clamp and bypass times. Post-operative 
variables included outcomes such as sepsis, bleeding, 
re-operation, and the development of acute kidney 
injury (AKI). The pre-operative, intra-operative and 
post-operative outcomes were compared to determine 
the effect each variable had on post-operative mortality. 
Results: Two hundred and seventeen patients under-
went mitral valve surgery at CMJAH between 1 January 
2015 and 31 December 2018. Four patients’ records 
were incomplete. RHD was found to be the primary 
aetiology for mitral valve surgery at CMJAH with a 
mortality rate of 6.1%. Pre-operative fi ndings that con-
tributed to mortality were: EuroSCORE>2%, pre-
operative ventilation, dialysis dependence, pre-opera-
tive inotropic support, chronic obstructive pulmonary 
disease, congestive cardiac failure, renal insuffi ciency, 
low ejection fraction and New York Heart Associa-
tion functional class ≥III. Post-operative fi ndings that 
contributed to increased mortality were prolonged 
mechanical ventilation, pneumonia, re-operation, AKI, 
sepsis, bleeding, and transfusion. Increased aortic 
clamping and cardiopulmonary bypass times increased 
the risk of prolonged mechanical ventilation, re-opera-
tions, pacemaker implantations, AKI, and bleeding.
Conclusions: RHD was found to be the primary aetiology 
for mitral valve surgery at CMJAH with a mortality of 
6.1%. Pre-operative, intra-operative and post-operative 
predictors of outcomes in this study confi rm observa-
tions made in other parts of the world. 
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bypass (CPB).(6) Platelets are activated and subsequently bind 
to the exposed subendothelium, the CPB circuit or to the 
circulating monocytes and neutrophils, resulting in a decrease in 
platelet numbers.(7) The decrease in platelet numbers and 
altered platelet function is the rationale behind the major 
blood loss encountered during cardiac surgery.(7,8)
Multiple studies report that CPB has negative effects on 
haemostasis and the inflammatory response.(7,9,10) The blood 
cell activation and plasma protein alteration that occurs during 
CPB increases bleeding time, post-operative blood loss and 
increases the risk for massive blood transfusion.(7) Bleeding 
occurs commonly in cardiac surgery and is a significant cause 
of morbidity and mortality.(11) Two to eight percent of cardiac 
reoperations are indicated for uncontrolled bleeding.(11-13) 
Prolonged cardiopulmonary bypass time (CPBT) was associ-
ated with haemostatic abnormalities.(7) CPBT >90 minutes 
resulted in higher mean blood losses peri-operatively.(7) Re-
operation in mitral valve surgery was closely linked to pro-
longed CPBT.(14) An African study identif ied CPB >120 min-
utes was associated with reduction in platelet counts in 
comparison with CPBT <60 minutes.(15)
In addition to the major blood loss attributed to CPB, there is 
a significant association with increased CPBT and the develop-
ment of acute kidney injury (AKI).(16) AKI develops in 2.8% of 
patients following valvular heart surgery.(6,17) In one study, 38.7% 
of patients who underwent mitral valve surgery had post-
operative AKI, and presented with pre-operative New York 
Heart Association (NYHA) functional class III and IV, a dilated 
left ventricle (LV) and low LV ejection fraction (LVEF), all of 
which lead to hypoperfusion of the kidneys and AKI.(18) AKI 
prolongs hospital stay and increases the risk of infectious 
complications and mortality.(17,18) Risk of infection significantly 
increases with prolonged CPBT.(10,14) Prolonged CPBT resulted 
in an increased incidence of prolonged mechanical ventilation, 
increasing the post-operative risk of pneumonia and peri-
operative infection.(19) Surgical site infection due to prolonged 
CPBT ranges from 0.3% - 8%.(20,21) Patients who developed 
post-operative infection had prolonged CPB and operative 
times.(20) Shorter operative times, higher haemoglobin (Hb) 
and higher haematocrit significantly decreased the post-opera-
tive risk of infection. The incidence of post-operative infection 
was 4.5%.(20)
Despite advances in surgical techniques, anaesthesia and critical 
care, cardiac surgery is associated with high peri-operative risk. 
Risk stratification scores in cardiac surgery are sophisticated 
and are used worldwide to determine peri-operative risk.(22) 
The European System for Cardiac Operative Risk Evaluation II 
(EuroSCORE II) has been validated in the UK, Europe and 
North America,(22) and shown to be predictive of peri-operative 
outcomes in cardiac surgery.(23) However, data from Africa 
describing the ability of risk scoring systems to predict peri-
operative outcomes in African patients undergoing cardiac 
surgery have not been validated.(22,24) Anaesthesiologists need 
to assess symptom severity and effort tolerance pre-opera-
tively to determine risk. Advanced NYHA functional class was 
a risk factor for early mortality.(26,27) Therefore, the aim of this 
study was to describe the peri-operative outcomes of patients 
that have undergone mitral valve surgery at the Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH).  
METHODS
This study was a retrospective, descriptive review of all 
patients who underwent mitral valve surgery at CMJAH 
between 1 January 2015 and 31 December 2018. A maximum 
of 60 patients undergo mitral valve surgery per annum at 
CMJAH. All patients above the age of 18-years-old were 
included in the study. Cardiac intensive care unit records 
including anaesthesia charts were assessed to describe pre-
operative, intra-operative and post-operative data of each 
patient included in the study. Pre-operative data included 
patient demographics and comorbidities. Intra-operative data 
included aortic clamp and bypass times. Post-operative vari-
ables assessed included outcomes such as sepsis, bleeding, 
re-operation and the development of AKI. The pre-operative, 
intra-operative and post-operative outcomes were then com-
pared to determine the effect each variable had on post-
operative mortality. 
STATA (version 15) was used to analyse the data. Descriptive 
statistics were used for pre-operative, intra-operative and post-
operative data. Categorical variables were described using 
frequencies and percentages. Inferential statistics were used 
to compare different variables. A p-value <0.05 was deemed 
statistically significant. The effect of categorical variables (pre-
operative demographics and post-operative outcomes) on 
mortality were analysed using the Fishers exact test due to the 
limited sample size. The Shapiro-Wilk test was used to test for 
the normality of distribution of the continuous variables (aortic 
clamping and bypass times). As the data was not normally 
distributed, medians and inter-quartile ranges were used to 
describe the continuous variables. The two-sample Wilcoxon 
Rank-Sum Mann-Whitney test was used to compare variables. 
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Approval (M220343) from the Human Research and Ethics 
Committee (Medical) and all other relevant authorities was 
obtained. Data was managed according to the standards stip-
ulated by the University of the Witwatersrand. RedCap® was 
the data management tool used to obtain information. Each 
patient was assigned a study number and a separate list of 
patient details was available only to the researcher. 
RESULTS
Two hundred and seventeen patients underwent mitral valve 
surgery at CMJAH between 1 January 2015 and 31 December 
2018. Four of the patients had incomplete records, therefore 
213 were included in the study. The pre-operative demographic 
data of these patients is described in Table 1. One hundred and 
thirty five patients (63.4%) were female and 78 were male; 
86.2% were <60 years of age. A large group of patients, 135 
(63.4%) did not have a documented EuroSCORE II. Of those 
with a documented EuroSCORE II, 71 (91%) had a score 
<2%, 6 (7.7%) had scores between 2% - 5% and 1 (1.3%) had 
a score >5%. Patients’ pre-operative comorbidities are des-
cribed in Table II. One hundred and eighty two patients (95.8%) 
had LVEF >35%. One hundred and fifty two (77.6%) had pul-
monary artery pressures (PAP) >30mmHg. RHD was diag-
nosed in 119 (55.9%) as the primary aetiology for patients 
undergoing mitral valve surgery. Ischaemic mitral regurgitation 
(IMR) was diagnosed in 81 (38%) as the main secondary 
aetiology. Sixty two (29.7%) patients had hypertension, 38 
(22.2%) had NYHA functional class ≥III, 31(15%) had previous 
cardiac surgery, 30 (14.4%) had hypercholesterolaemia and 30 
(14.4%) had congestive cardiac failure. Serum creatinine 
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TABLE I: Pre-operative demographic data 
of mitral valve surgery patients at CMJAH.
Demographics Variable Frequency Missing data
EuroScore II (%)
<2% 71 (91.03)




<60 175 (82.16) 0
>60 38 (17.84)
Sex






TABLE II: Pre-operative comorbidities.



























































< Class III 133 (77.78)
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>110μmol/L was observed in 24 (11.8%) patients, 22 (11.1%) 
had abnormal renal function, and 21 (10.1%) presented with LV 
dysfunction. 18 (8.7%) were smokers and 15 (7.2%) presented 
with pre-operative chronic obstructive pulmonary disease 
(COPD). Diabetes was present in 21 (10.2%) patients and 9 
(4.4%) patients had ischaemic heart disease.
One hundred and five patients (75%) were started on inotropic 
support and 48 (35.9%) had intra-operative blood transfusions. 
The mean aortic clamping and bypass time were 97.01 and 
144.19 minutes, respectively. 
Arrythmias were documented in 113 (54.1%) patients, 41 
(19.3%) were transfused post-operatively, and AKI was present 
in 36 (17%) – Table III. Twenty-eight (18.2%) had significant 
bleeding and 27 (12.7%) had prolonged mechanical ventilation. 
Re-operations were done in 26 (12.2%) patients, 26 (12.4%) 
had pacemakers implanted post-operatively, 24 (11.5%) had 
sepsis, and cerebrovascular accidents (CVA) were noted in 13 
(6.1%) patients. 13 (6.1%) patients died, 9 (4.3%) developed 
pneumonia and 1 (0.5%) patient had hypertension post-
operatively. 
Pre-operative data that was associated with mortality included 
dialysis dependence, pre-operative inotropic support, pre-
operative ventilation, LVEF <35%, COPD, NYHA functional 
class ≥III, renal insufficiency, cardiac failure, and a EuroSCORE II 
>2% - Table IV. Post-operative features that were indepen-
dent risk factors for mortality were prolonged mechanical 
ventilation, re-operation, bleeding, transfusion, AKI, sepsis, and 
pneumonia – Table V. Results from univariate analysis showed 
no signif icant association between aortic clamping time and 
post-operative outcomes. However, CPBT had a significant 
influence on post-operative outcomes. Post-operative variables 
associated with increased CPBT were prolonged mechanical 
ventilation, re-operation, pacemaker use, AKI and bleeding – 
Table VI.  
DISCUSSION
Published data approximate the peri-operative mortality rate of 
mitral valve surgery to be 3%, dependent on the population 
and the peri-operative risk of the patient prior to surgery.(3,28) 
In contrast to internationally published data, our peri-operative 
mortality rate was 6.1%. RHD is the main form of valve heart 
disease in Africa. Multiple studies across Africa confirm that 
RHD is the primary cause of morbidity and mortality seen in 
younger populations undergoing cardiac surgery.(2) Findings 
from our study are consistent with other data from Africa, 
where RHD is the primary indication for mitral valve surgery, 
commonly performed in patients below the age of 60 years. 
Advanced age and NYHA class ≥III have been shown to 
increase peri-operative mortality of valve surgery.(26,27,29) Our 
study did not show age having a direct effect on peri-operative 
mortality but confirmed that NYHA class ≥III is an indepen-
dent risk factor for mortality, likely due to more patients in our 
study being younger than 60 years and a relatively small sample 
size. We also found that LVEF <35% was a strong predictor of 
mortality, confirming the importance of pre-operative echo-
cardiography and functional assessment of the patient. An 
increase in mortality was noted in patients presenting pre-
operatively with COPD, heart failure and need for inotropic 
support. A limitation of our study is the lack of documentation 
of the rationale for pre-operative inotropic support. It was 



























































difficult to determine whether inotropic support was an inde-
pendent risk factor for mortality or if the pre-operative state 
requiring inotropic support was a greater contributor to the 
increase noted.
LV dysfunction, atrial fibrillation and pulmonary hypertension 
are identified risk factors for peri-operative morbidity and mor-
tality.(30) In our study, arrythmias and pulmonary arterial pres-
sures >30mmHg were commonly documented. A limitation of 
our study is that pulmonary artery pressures were only docu-
mented prior to surgery in most patients, making it difficult to 
assess whether increasing pressures had a direct correlation 
with the risk of mortality.
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TABLE IV: Association between pre-operative factors and mortality.
Variable Class Dead n (%) Alive n (%) P-value
EuroScore
< 2 % 1 (1.41) 70 (98.59)
0.0202- 5 % 2 (3.33) 4 (66.7)
>5 % 0 (0.00) 1 (100.00)
Pre-operative ventilation
No 8 (3.96) 194 (96.04)
0.028
Yes 2 (33.33) 4 (66.67)
Dialysis dependent
No 9 (4.35) 198 (95.65)
0.048
Yes 1 (100.00) 0 (0.00)
Pre-operative inotropic support
No 7 (3.45) 196 (96.55)
0.01
Yes 2 (50.00) 2 (50.00)
PAP (mmHg)
<30 4 (9.09) 40 (90.91)
0.27
>30 7 (4.61) 145 (95.39)
LV dysfunction
No 8 (4.30) 178 (95.70)
0.27
Yes 2(9.52) 19 (90.48)
Smoker
No 9 (4.74) 181 (95.26)
0.60
Yes 1 (5.56) 17 (94.44)
COPD
No 8 (4.12) 186 (95.88)
0.035
Yes 3 (20.00) 12 (80.00)
CCF
No 4 (2.25) 174 (97.75)
0.004
Yes 5 (16.67) 25 (83.33)
Renal insuffi ciency
No 5 (2.82) 172 (97.18)
0.046
Yes 3 (18.64) 19 (86.36)
EF%
<35% 2 (25.00) 6 (75.00)
0.03
>35% 5 (2.75) 177 (97.25)
Aetiology (primary)
RHD 4 (3.36) 115 (96.64)
0.043
Myxomatous 0 (0.00) 18 (100.00)
Endocarditis 4 (21.05) 15 (78.95)
MV prolapse 2 (7.14) 26 (92.86)
Other 2 (8.00) 23 (92.00)
Aetiology (secondary)
IMR 10 (5.52) 171 (94.48)
0.29DCMO 1 (25.00) 3 (75.00)
Other 1 (5.26) 18 (94.74)
NYHA
< Class 3 2 (1.50) 131 (98.50)
0.006













Risk scoring systems for predicting peri-operative morbidity and 
mortality are mandatory.(31) There are no risk scoring systems 
validated in large population groups like sub-Saharan Africa.(22,24) 
In our study, the EuroSCORE II was used as a pre-operative 
assessment to predict the risk of mortality. Unfortunately, there 
were many missing data and very few patient records had a 
documented EuroSCORE II score. We suggest that a risk 
scoring system be validated in Africa to assist in predicting 
mortality in our population.
AKI and its detrimental peri-operative effects during mitral valve 
surgery have been extensively reviewed.(6,16,17) Patients under-
going mitral valve surgery commonly display a decrease in the 
volume of blood ejected from the mitral valve due to regurgi-
tation, resulting in poor perfusion to the kidneys. A third of 
patients who underwent mitral valve surgery developed AKI,(18) 
and patients presenting with AKI had increased prevalence of 
hypertension and diabetes. Although patients in our study did 
not have high rates of hypertension and diabetes, AKI proved 
to be a major independent predictor of mortality. We also 
found that increased CPBT of ≥157.5 minutes and aortic 
clamping times ≥105.5 minutes directly increased the risk of 
AKI, which is in keeping with prior reports.(6,18,32)
Increased CPBT is an independent risk factor for bleeding and 
subsequent blood transfusion following cardiac surgery.(7,15) In 
addition to the above findings, our study confirmed that 
increased CPBT and aortic clamping times increased the risk 
of prolonged mechanical ventilation and subsequent pneu-
monia.(19) A novel finding in our series is the increased use of 
pacemakers associated with increased bypass and aortic 
clamping times. Contrary to previous studies, we did not find 
that sepsis was directly linked to increased CPBT and aortic 
clamping times. Sepsis, however, was a strong predictor of peri-
operative mortality seen in our study. 
The economic cost of transfusing blood products and asso-
ciated complications are high.(33) The limitation in this study is 
that data on the number of blood products transfused was not 
collected nor were the negative outcomes of transfusion 
documented. 








Yes 7 (6.19) 106 (93.81)
1.00
No 5 (5.21) 91 (94.79)
Prolonged mechanical ventilation
Yes 10 (37.04) 17 (62.96)
<0.01
No 2 (1.08) 183 (98.92)
Pneumonia
Yes 3 (3.33) 6 (66.67)
<0.01
No 8 (3.96) 194(96.04)
CVA
Yes 2 (15.38) 11 (84.62)
0.16
No 10 (5.03) 189 (94.97)
Re-operation
Yes 9 (34.62) 17 (65.38)
<0.01
No 4 (2.14) 183(97.86)
Pacemaker insertion
Yes 1 (3.85) 25 (96.15)
1.00
No 10 (5.43) 174 (94.57)
AKI
Yes 7 (19.44) 29 (80.56)
<0.01
No 5 (2.84) 171 (97.16)
Sepsis
Yes 7 (29.17) 17 (70.83)
<0.01
No 3 (1.61) 183 (98.39)
Bleeding
Yes 8 (28.57) 20 (71.43)
<0.01
No 5 (2.70) 180 (97.30)
Transfusion
Yes 8 (19.51) 33 (80.49)
<0.01
No 4 (2.34) 167 (97.66)
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The peri-operative outcomes of mitral valve surgery found in 
this study can be avoided, anticipated, and effectively managed. 
A multidisciplinary team of anaesthesiologists, cardiac surgeons, 
physicians, nurses and allied health professionals are needed to 
decrease morbidity and assess each patient pre-operatively for 
the risk of peri-operative mortality.
CONCLUSION
RHD was the predominant primary aetiology for mitral valve 
surgery in our institution with an overall mortality rate of 6.1%. 
Pre-operative findings that contributed to increased mortality 
were EuroSCORE II ≥2%, pre-operative ventilation, dialysis 
dependence, pre-operative inotropic support, COPD, heart 
failure, renal insuff iciency, LVEF <35% and NYHA ≥III. Post-
operative findings that contributed to increased mortality were 
prolonged mechanical ventilation, pneumonia, reoperation, 
AKI, sepsis, bleeding, and transfusion. Increased aortic clamping 
and CPBT significantly increased the risk of prolonged mech-
anical ventilation, re-operations, use of pacemakers, AKI, and 
bleeding.
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